Wed Jan 22, 2020 04:04
English | 繁體 | 简体
Click here to toggle text size
FOSUN PHARMA gets approval for FCN-647 capsules clinical trial
14 Jan 2020
(Infocast News) Fosun Pharmaceutical (02196) has received the approval for clinical trial for FCN-647 capsules for the treatment of relapsed or refractory B-lymphocyte malignancies from the National Medical Products Administration. Fosun Pharmaceutical intends to conduct phase I clinical trial for the new drug in the PRC upon meeting the conditions shortly.

(WL)
© Copyright Quamnet. All rights reserved. Republish the contents in whole or in part other than the authorized methods below, Quamnet reserves the right to proceed legal action.
Market Update
A founding member of:
China Tonghai IR:
Sitemap  |  About Us  |  Contact Us  |  Disclaimers     English | 繁體 | 简体  
Tonghai Financial:
China Tonghai International Financial Limited  |  China Tonghai Capital  |  China Tonghai Securities
Oceanwide Financial Management   |  Quamnet
 
Information of TonghaiIR (Investor Relations):
[Hong Kong Listed Company Information] [Financial News] [Announcement Alerts] [Free Delayed Stock Quote] [Chart]
[Hong Kong stock information]

TonghaiIR (Investor Relations) Services:
[Listed Companies Information] [Listed Companies Financial Information] [Listed Companies Announcements]
[Listed Companies Circulars] [Listed Companies News] [Press Releases] [Listed Companies Event Calendar]
[Listed Companies Presentations] [Proxy Forms]

China Tonghai IR (Investor Relations):
[Securities Firms] [Fund Houses] [Venture Capitals] [Financial Public Relations Agencies] [Financial Printers]
Investor Relations Dictionary:
[Listed Companies Result Announcement] [Financial Report] [Interim Report] [Annual General Meeting]
[Extraordinary General Meeting] [Board Meeting] [Annual Report] [Contact Listed Companies Investor Relations]
[Company Information Sheet] [Next Day Disclosure Return] [News Release] [IPO] [Prospectus] [Stock Quote] [Trading Volume]